Immunoglobulin replacement treatment by rapid subcutaneous infusion

Area of Science:

• Pediatric Immunology
• Immunotherapy
• Pharmacology

Background:

• Intravenous immunoglobulin (IVIG) is a standard treatment for pediatric immunodeficiencies but presents challenges like poor venous access and hospital admissions.
• Subcutaneous immunoglobulin (SCIG) infusion has demonstrated efficacy in adults with primary immunodeficiency.

Purpose of the Study:

• To evaluate the efficacy, safety, and tolerability of SCIG in children with immunodeficiencies.
• To compare trough IgG concentrations between SCIG and IVIG treatments.
• To assess the impact of SCIG on patients' quality of life.

Main Methods:

• Retrospective analysis of 26 children treated with SCIG for a median of two years.
• Comparison of trough IgG levels between SCIG and prior IVIG treatment in 15 children.
• Monitoring for systemic adverse reactions and hospital admissions.

Main Results:

• SCIG treatment maintained comparable trough IgG concentrations to IVIG during maintenance therapy.
• No systemic or severe adverse reactions requiring hospital admission were reported.
• All families reported a significant improvement in their child's quality of life.

Conclusions:

• SCIG appears to be an effective, convenient, and well-tolerated alternative to IVIG for children with immunodeficiencies.
• Initial loading doses of SCIG or IVIG may be necessary for severe hypogammaglobulinaemia.
• Larger prospective studies are needed to establish the definitive role of SCIG in managing immunodeficiencies.